- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Decision publication date:
- 13 June 2024
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Rationale:
- Topic in appraisal.
- Process:
- STA Standard
- ID number:
- 6292
Project Team
- Project lead
- Kate Moore
Email enquiries
If you have any queries please email TACommD@nice.org.uk
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Stakeholders
- Companies sponsors
- Bayer (larotrectinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- AMMF - The Cholangiocarcinoma Charity
- Bowel Cancer UK
- Breast Cancer Now
- Sarcoma UK
- Professional groups
- Association of Cancer Physicians
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- None
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 September 2026 | Following the committee meeting on 9 September 2026, the company has been in discussion with NICE regarding larotrectinib for treating NTRK-fusion positive solid tumours. NICE is pausing this appraisal to allow the company to provide additional analysis requested by the committee to inform its decision-making. - Note added to the project documents |
| 09 September 2026 | Declaration of interests |
| 09 September 2026 | Committee meeting: 2 |
| 01 April 2026 - 24 April 2026 | Draft guidance |
| 04 March 2026 | Committee meeting: 1 |
| 04 August 2025 | Invitation to participate |
| 04 August 2025 | In progress. Invitation to participate |
| 13 June 2025 - 10 July 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 13 June 2024 | Awaiting development |
| 13 June 2024 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. - Note added to the project documents |
For further information on our processes and methods, please see our CHTE processes and methods manual